Abstract
To elucidate the role of early insulin response in postprandial hyperlipidemia, we examined triglyceride (TG) and remnant-like particle triglyceride (RLP-TG) levels, using a meal tolerance test (MTT) with or without the administration of nateglinide (NAT). The MTTs were performed 2 d apart in 36 drug-naive patients with type 2 diabetes who had been hospitalized for glycemic control while receiving diet therapy. Before the second MTT, patients were treated with 90 mg NAT. Treatment with NAT was associated with a significant increase in insulin levels in the treated patients 1 h after the test meal, compared to levels in non-treatment. NAT treatment was also associated with a significant decrease in the level of free fatty acids 1 and 2 h after the meal, and with a significant decrease in plasma glucose levels 1, 2, and 4 h after the meal, compared to those in non-treatment. During the first MTT with NAT non-treatment, 13 patients showed serum TG levels of 200 mg/dL or greater when measured 2 h after the meal. In these 13 patients, NAT administration produced a significant decrease in TG levels 1, 2, and 6 h after the meal, as well as a significant reduction in RLP-TG levels 1 and 2 h after the meal. NAT administration was also associated with significant reductions in area under the curve (ΔAUC) for TG and RLP-TG. These results suggest that, in a clinical setting, the early insulin response is closely associated with both postprandial glucose and postprandial lipid metabolism in Japanese patients with type 2 diabetes.
Similar content being viewed by others
References
The DECODE Study Group. European Diabetes Epidemiology Group. (1999). Lancet 354, 617–621.
DECODE Study Group, the European Diabetes Epidemiology Group. (2001). Arch. Intern. Med. 161, 397–405.
Teno, S., Uto, Y., Nagashima, H., et al. (2000). Diabetes Care 23, 1401–1406.
Ross, R. (1993). Nature 362, 801–809.
Ceriello, A., Taboga, C., Tonutti, L., et al. (2002). Circulation 106, 1211–1218.
Tanaka, A., Tomie, N., Nakano, T., et al. (1998). Clin. Chim. Acta 275, 43–52.
Ai, M., Tanaka, A., Ogita, K., et al. (2000). J. Clin. Endocrinol. Metab. 85, 3557–3560.
Ai, M., Tanaka, A., Ogita, K., et al. (2001). J. Am. Coll. Cardiol. 38, 1628–1632.
McNamara, J. R., Shah, P. K., Nakajima, K., et al. (2001). Atherosclerosis 154, 229–236.
Kugiyama, K., Doi, H., Takazoe, K., et al. (1999). Circulation 99, 2858–2860.
Schaefer, E. J., McNamara, J. R., Shah, P. K., et al. (2002). Diabetes Care 25, 989–994.
Horton, E. S., Clinkingbeard, C., Gatlin, M., Foley, J., Mallows, S., and Shen, S. (2000). Diabetes Care 23, 1660–1665.
Mine, T., Miura, K., Kitahara, Y., Okano, A., and Kawamori, R. (2002). Biol. Pharm. Bull. 25, 1414–1416.
Esposito, K., Giugliano, D., Nappo, F., Marfella, R., and Campanian Postprandial Hyperglycemia Study Group. (2004). Circulation 110, 214–219.
Vakkilainen, J., Mero, N., Schweizer, A., Foley, J. E., and Taskinen, M.-R. (2002). Diabetes Metab. Res. Rev. 18, 484–490.
Mori, Y., Kitahara, Y., Miura, K., Mine, T., and Tajima, N. (2004). Diabetes Obes. Metab. 6, 422–431.
Mori, Y., Kitahara, Y., Miura, K., and Tajima, N. (2004). Endocrine 23, 39–44.
Dimitriadis, G., Boutati, E., Lambadiari, V., et al. (2004). Eur. J. Clin. Invest. 34, 490–497.
Califf, R. M. (2003). Eur. Heart J. Suppl. 5(Suppl C), C13-C18.
Ogawa, S., Takeuchi, K., Sugimura, K., et al. (2000). Metabolism 49, 331–334.
Banauch, D., Brummer, W., Ebeling, W., et al. (1975). Z. Klin. Chem. Klin. Biochem. 13, 101–107.
Nakajima, K., Saito, T., Tamura, A., et al. (1993). Clin. Chim. Acta 223, 53–71.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mori, Y., Kuriyama, G. & Tajima, N. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test. Endocr 25, 203–206 (2004). https://doi.org/10.1385/ENDO:25:3:203
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:25:3:203